Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

I Epstein

Showing results (911-920 of 1,132) with videos related to

Pageof 114
Sort By:
Journal of Immunology (Baltimore, Md. : 1950)|November 15, 1988
Subtypes of helper cells. Non-inflammatory type 1 helper T cellsR L Wong, N H Ruddle, S J Padula, et al.
Urology|January 11, 2011
ProPSA and diagnostic biopsy tissue DNA content combination improves accuracy to predict need for prostate cancer treatment among men enrolled in an active surveillance programSumit Isharwal, Danil V Makarov, Lori J Sokoll, et al.
Cancer|December 12, 2003
Quantitative alterations in nuclear structure predict prostate carcinoma distant metastasis and death in men with biochemical recurrence after radical prostatectomyMasood A Khan, Patrick C Walsh, M Craig Miller, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 26, 2009
Pro-prostate-specific antigen measurements in serum and tissue are associated with treatment necessity among men enrolled in expectant management for prostate cancerDanil V Makarov, Sumit Isharwal, Lori J Sokoll, et al.
The Journal of Urology|December 17, 2009
Accuracy of PCA3 measurement in predicting short-term biopsy progression in an active surveillance programJeffrey J Tosoian, Stacy Loeb, Anna Kettermann, et al.
BJU International|July 2, 2016
Prediction of pathological stage based on clinical stage, serum prostate-specific antigen, and biopsy Gleason score: Partin Tables in the contemporary eraJeffrey J Tosoian, Meera Chappidi, Zhaoyong Feng, et al.
Urology|October 18, 2002
Complexed prostate-specific antigen as a staging tool for prostate cancer: a prospective study in 420 menLori J Sokoll, Leslie A Mangold, Alan W Partin, et al.
Bulletin of Experimental Biology and Medicine|September 2, 2003
Use of ANAR for the therapy of opium withdrawal syndromeA G Gofman, E N Krylov, T A Kozhinova, et al.
The Journal of Urology|April 1, 1988
Prostate specific antigen in the preoperative and postoperative evaluation of localized prostatic cancer treated with radical prostatectomyJ E Oesterling, D W Chan, J I Epstein, et al.
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|June 26, 1998
CG island methylation changes near the GSTP1 gene in prostatic intraepithelial neoplasiaJ D Brooks, M Weinstein, X Lin, et al.
Pageof 114

Showing results (911-920 of 1,132) with videos related to

Sort By:
Pageof 114
Journal of Immunology (Baltimore, Md. : 1950)|November 15, 1988
Subtypes of helper cells. Non-inflammatory type 1 helper T cellsR L Wong, N H Ruddle, S J Padula, et al.
Urology|January 11, 2011
ProPSA and diagnostic biopsy tissue DNA content combination improves accuracy to predict need for prostate cancer treatment among men enrolled in an active surveillance programSumit Isharwal, Danil V Makarov, Lori J Sokoll, et al.
Cancer|December 12, 2003
Quantitative alterations in nuclear structure predict prostate carcinoma distant metastasis and death in men with biochemical recurrence after radical prostatectomyMasood A Khan, Patrick C Walsh, M Craig Miller, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 26, 2009
Pro-prostate-specific antigen measurements in serum and tissue are associated with treatment necessity among men enrolled in expectant management for prostate cancerDanil V Makarov, Sumit Isharwal, Lori J Sokoll, et al.
The Journal of Urology|December 17, 2009
Accuracy of PCA3 measurement in predicting short-term biopsy progression in an active surveillance programJeffrey J Tosoian, Stacy Loeb, Anna Kettermann, et al.
BJU International|July 2, 2016
Prediction of pathological stage based on clinical stage, serum prostate-specific antigen, and biopsy Gleason score: Partin Tables in the contemporary eraJeffrey J Tosoian, Meera Chappidi, Zhaoyong Feng, et al.
Urology|October 18, 2002
Complexed prostate-specific antigen as a staging tool for prostate cancer: a prospective study in 420 menLori J Sokoll, Leslie A Mangold, Alan W Partin, et al.
Bulletin of Experimental Biology and Medicine|September 2, 2003
Use of ANAR for the therapy of opium withdrawal syndromeA G Gofman, E N Krylov, T A Kozhinova, et al.
The Journal of Urology|April 1, 1988
Prostate specific antigen in the preoperative and postoperative evaluation of localized prostatic cancer treated with radical prostatectomyJ E Oesterling, D W Chan, J I Epstein, et al.
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|June 26, 1998
CG island methylation changes near the GSTP1 gene in prostatic intraepithelial neoplasiaJ D Brooks, M Weinstein, X Lin, et al.
Pageof 114